The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia

Future Oncology

Volumn 11, Issue 10, 2015, Pages 1567-1582

  Yousefi, Mehdi ^a,b   Movassaghpour, Ali Akbar ^b   Shamsasenjan, Karim ^b   Ghalamfarsa, Ghasem ^c   Sadreddini, Sanam ^a   Jadidi Niaragh, Farhad ^d   Hojjat Farsangi, Mohammad ^e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

balance; chronic lymphocytic leukemia; IL 17; Th17; Tregs

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LEUKEMOGENESIS; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; UPREGULATION; ANIMAL; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TUMOR MICROENVIRONMENT;

EID: 84929241181     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.298     Document Type: Article

References (150)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1), 265-276 (2006).
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352(8), 804-815 (2005).
3. Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol. Immun. 55(2), 210-220 (2006).
4. Jadidi-Niaragh F, Yousefi M, Memarian A et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest. 31(2), 121-131 (2013).
5. Zaknoen S, Kay N. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev. 4(3), 165-174 (1990).
6. Riches JC, Ramsay AG, Gribben JG. Immune reconstitution in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 7(1), 13-20 (2012).
7. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br. J. Haematol. 96(4), 733-735 (1997).
8. Kay NE, Han L, Bone N, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br. J. Haematol. 112(3), 760-767 (2001).
9. Cerutti A, Kim EC, Shah S et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat. Immunol. 2(2), 150-156 (2001).
10. Haabeth OaW, Lorvik KB, Hammarström C et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2, 240 (2011).
11. Podhorecka M, Dmoszynska A, Rolinski J, Wasik E. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia: the three-color flow cytometry analysis. Leuk. Res. 26(7), 657-660 (2002).
12. Hill S, Peters S, Ayliffe M, Merceica J, Bansal A. Reduced IL-4 and interferon-gamma (IFN-) expression by CD4 T cells in patients with chronic lymphocytic leukaemia. Clin. Exp. Immunol. 117, 8-11 (1999).
13. Gallego A, Vargas J, Castejon R et al. Production of intracellular IL-2, TNF-α, and IFN-γ by T cells in B-CLL. Clin. Cytom. 56(1), 23-29 (2003).
14. Granziero L, Ghia P, Circosta P et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9), 2777-2783 (2001).
15. Herishanu Y, Katz B-Z, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol. Oncol. Clin. North. Am. 27(2), 173-206 (2013).
16. Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Invest. 115(7), 1797-1805 (2005).
17. Orsini E, Pasquale A, Maggio R et al. Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19+ cells in vivo and in vitro. Br. J. Haematol. 125(6), 720-728 (2004).
18. Ramsay AG, Johnson AJ, Lee AM et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118(7), 2427-2437 (2008).
19. Ravandi F, O'brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol. Immun. 55(2), 197-209 (2006).
20. Foa R, Fierro M, Lusso P et al. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8. 28. Br. J. Haematol. 62(1), 151-154 (1986).
21. Yan X-J, Dozmorov I, Li W et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 118(19), 5201-5210 (2011).
22. Jadidi-Niaragh F, Mirshafiey A. The deviated balance between regulatory T cell and Th17 in autoimmunity. Immunopharmacol. Immunotoxicol. 34(5), 727-739 (2012).
23. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106(6), 2018-2025 (2005).
24. Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol. Rep. 20(3), 677-682 (2008).
25. Jadidi-Niaragh F, Ghalamfarsa G, Yousefi M, Tabrizi MH, Shokri F. Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. Tumour Biol. 34(4), 2031-2039 (2013).
26. Miller JF. Effect of neonatal thymectomy on the immunological responsiveness of the mouse. Proc. R. Soc. Lond. B: Biol. Sci. 156(964), 415-428 (1962).
27. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18(5), 723 (1970).
28. Sadlack B, Löhler J, Schorle H et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25(11), 3053-3059 (1995).
29. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
30. Larkin J, Rankin AL, Picca CC et al. CD4+ CD25+ regulatory T cell repertoire formation shaped by differential presentation of peptides from a self-antigen. J. Immunol. 180(4), 2149-2157 (2008).
31. Liu X, Nguyen P, Liu W et al. T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3+ regulatory T cells. Immunity 31(6), 909-920 (2009).
32. Singer A, Adoro S, Park J-H. Lineage fate and intense debate: myths, models and mechanisms of CD4-versus CD8-lineage choice. Nat. Rev. Immunol. 8(10), 788-801 (2008).
33. Jadidi-Niaragh F, Mirshafiey A. Regulatory T-cell as orchestra leader in immunosuppression process of multiple sclerosis. Immunopharmacol. Immunotoxicol. 33(3), 545-567 (2011).
34. Abbas AK, Benoist C, Bluestone JA et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14(4), 307-308 (2013).
35. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6(2), 152-162 (2005).
36. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+ CD25+ regulatory T cells. J. Exp. Med. 201(7), 1061-1067 (2005).
37. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202(10), 1375-1386 (2005).
38. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2,-7, and-15, but not thymic stromal lymphopoeitin, redundantly govern CD4+ Foxp3+ regulatory T cell development. J. Immunol. 181(5), 3285-3290 (2008).
39. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
40. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, Von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6(12), 1219-1227 (2005).
41. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu X-Z. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 117(11), 3096-3103 (2011).
42. Lathrop SK, Santacruz NA, Pham D, Luo J, Hsieh C-S. Antigen-specific peripheral shaping of the natural regulatory T cell population. J. Exp. Med. 205(13), 3105-3117 (2008).
43. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs-role in immune homeostasis and autoimmunity. Front. Immunol. 7(4), 232 (2013).
44. Yadav M, Louvet C, Davini D et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J. Exp. Med. 209(10), 1713-1722 (2012).
45. Caridade M, Graca L, Ribeiro RM. Mechanisms underlying CD4+ Treg immune regulation in the adult: from experiments to models. Front. Immunol. 18(4), 378 (2013).
46. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 74(1), 1-13 (2011).
47. Ghoreschi K, Laurence A, Yang X-P et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature 467(7318), 967-971 (2010).
48. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203(7), 1685-1691 (2006).
49. Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-β are required for differentiation of human TH17 cells. Nature 454(7202), 350-352 (2008).
50. Zielinski CE, Mele F, Aschenbrenner D et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1. Nature 484(7395), 514-518 (2012).
51. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204(8), 1849-1861 (2007).
52. Maggi L, Santarlasci V, Capone M et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur. J. Immunol. 42(12), 3180-3188 (2012).
53. Wang Y, Godec J, Ben-Aissa K et al. The transcription factors T-bet and Runx are required for the ontogeny of pathogenic interferon-γ-producing T helper 17 cells. Immunity 40(3), 355-366 (2014).
54. El-Behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharm. 5(2), 189-197 (2010).
55. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5, 276 (2014).
56. Yang XO, Pappu BP, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28(1), 29-39 (2008).
57. Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282(13), 9358-9363 (2007).
58. Ivanov II, Mckenzie BS, Zhou L et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6), 1121-1133 (2006).
59. Brüstle A, Heink S, Huber M et al. The development of inflammatory TH-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8(9), 958-966 (2007).
60. Schraml BU, Hildner K, Ise W et al. The AP-1 transcription factor Batf controls TH17 differentiation. Nature 460(7253), 405-409 (2009).
61. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol. 9(11), 1297-1306 (2008).
62. Bauquet AT, Jin H, Paterson AM et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat. Immunol. 10(2), 167-175 (2008).
63. Quintana FJ, Basso AS, Iglesias AH et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191), 65-71 (2008).
64. Dang EV, Barbi J, Yang H-Y et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 146(5), 772-784 (2011).
65. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6(11), 1123-1132 (2005).
66. Stumhofer JS, Laurence A, Wilson EH et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7(9), 937-945 (2006).
67. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118(5), 1680-1690 (2008).
68. Chen Z, Laurence A, Kanno Y et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl Acad. Sci. USA 103(21), 8137-8142 (2006).
69. Moisan J, Grenningloh R, Bettelli E, Oukka M, Ho I-C. Ets-1 is a negative regulator of Th17 differentiation. J. Exp. Med. 204(12), 2825-2835 (2007).
70. Giannopoulos K, Schmitt M, Własiuk P et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 22(1), 222-224 (2007).
71. Jak M, Mous R, Remmerswaal EB et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk. Lymphoma 50(5), 788-801 (2009).
72. Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 117(10), 2163-2169 (2011).
73. D'arena G, Laurenti L, Minervini MM et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk. Res. 35(3), 363-368 (2011).
74. Piper K, Karanth M, Mclarnon A et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin. Exp. Immunol. 166(2), 154-163 (2011).
75. Perry C, Herishanu Y, Hazan-Halevy I et al. Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 53(9), 1807-1810 (2012).
76. Lad DP, Varma S, Varma N, Sachdeva MUS, Bose P, Malhotra P. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk. Lymphoma 54(5), 1012-1019 (2013).
77. Biancotto A, Dagur PK, Fuchs JC, Wiestner A, Bagwell CB, Mccoy JP. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod. Pathol. 25(2), 246-259 (2011).
78. Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8+ PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4: CD8 ratios and disease progression. Clin. Cancer Res. 18(3), 678-687 (2012).
79. Lindqvist CA, Christiansson LH, Thörn I et al. Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 133(3), 296-306 (2011).
80. Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Strömberg U, Loskog AS. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 131(3), 371-376 (2010).
81. Rissiek A, Schulze C, Bacher U et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. Int. J. Cancer 135(10), 2370-2379 (2014).
82. Skórka K, Bhattacharya N, Własiuk P et al. Thalidomide regulation of NF-κB proteins limits tregs activity in chronic lymphocytic leukemia. Adv. Clin. Exp. Med. 23(1), 25-32 (2013).
83. Piechnik A, Dmoszynska A, Omiotek M et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int. J. Cancer 133(6), 1489-1496 (2013).
84. Palma M, Hansson L, Choudhury A et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol. Immun. 61(6), 865-879 (2012).
85. Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med. Oncol. 29(5), 3561-3569 (2012).
86. Giannoni P, Pietra G, Travaini G et al. Chronic lymphocytic leukemia nurse-like cells express the hepatocyte growth factor receptor (c-MET) and indoleamine 2, 3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 99 (6), 1078-1087 (2014).
87. Ghalamfarsa G, Hadinia A, Yousefi M, Jadidi-Niaragh F. The role of natural killer T cells in B cell malignancies. Tumour Biol. 34(3), 1349-1360 (2013).
88. Dhodapkar KM, Barbuto S, Matthews P et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112(7), 2878-2885 (2008).
89. Gnerlich JL, Mitchem JB, Weir JS et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J. Immunol. 185(7), 4063-4071 (2010).
90. Prabhala RH, Pelluru D, Fulciniti M et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115(26), 5385-5392 (2010).
91. Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69(13), 5522-5530 (2009).
92. Giannopoulos K, Własiuk P, Dmoszyńska A, Roliński J, Schmitt M. Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia. Folia. Histochem. Cytobiol. 49(1), 161-160 (2011).
93. Idler I, Giannopoulos K, Zenz T et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br. J. Haematol. 148(6), 948-950 (2010).
94. Jadidi-Niaragh F, Ghalamfarsa G, Memarian A et al. Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumour Biol. 34(2), 929-940 (2013).
95. Cha Z, Zang Y, Guo H et al. Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia. Tumour Biol. 34(6), 3579-3585 (2013).
96. Ghalamfarsa G, Jadidi-Niaragh F, Hojjat-Farsangi M et al. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. Cytokine 62(3), 439-445 (2013).
97. Jain P, Javdan M, Feger FK et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97(4), 599-607 (2012).
98. Hus I, Bojarska-Junak A, Chocholska S et al. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. PLoS One 8(11), e78091 (2013).
99. Tajima M, Wakita D, Satoh T, Kitamura H, Nishimura T. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12. Int. Immunol. 23(12), 751-9 (2011).
100. Hamaï A, Pignon P, Raimbaud I et al. Human TH17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo. Cancer Res. 72(5), 1059-1063 (2012).
101. Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, Mirshafiey A. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis 2012, 805875 (2012).
102. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity 26(5), 579-591 (2007).
103. Tang D, Niu Q, Zeng T et al. [Ratio balance of Th17 and Treg cells in peripheral blood of patients with chronic lymphocytic leukemia]. Zhongguo shi yan xue ye xue za zhi 21(2), 329-333 (2013).
104. Fletcher JM, Lonergan R, Costelloe L et al. CD39+ Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183(11), 7602-7610 (2009).
105. Ye Z-J, Zhou Q, Zhang J-C et al. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAPdependent mechanism. Respir. Res. 12(77), 1-10 (2011).
106. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187(2), 676-683 (2011).
107. Pulte D, Furman RR, Broekman MJ et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 11(4), 367-372 (2011).
108. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J. Exp. Med. 179(3), 999-1004 (1994).
109. Huber S, Gagliani N, Esplugues E et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3- and Foxp3+ regulatory CD4+ T cells in an interleukin-10 dependent manner. Immunity 34(4), 554 (2011).
110. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14(1), R32 (2012).
111. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249(1), 43-58 (2012).
112. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39 (2012).
113. Zent CS, Laplant BR, Johnston PB et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 116(9), 2201-2207 (2010).
114. Shi LZ, Wang R, Huang G et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208(7), 1367-1376 (2011).
115. Shachar I, Cohen S, Marom A, Becker-Herman S. Regulation of CLL survival by hypoxia-inducible factor and its target genes. FEBS Lett. 586(18), 2906-2910 (2012).
116. Michalek RD, Gerriets VA, Jacobs SR et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186(6), 3299-3303 (2011).
117. Tung S, Shi Y, Wong K et al. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood 122(6), 969-980 (2013).
118. Lee WH, Kim SG. AMPK-dependent metabolic regulation by PPAR agonists. PPAR Res. 2010, pii: 549101 (2010).
119. Campàs C, López JM, Santidrián AF et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101(9), 3674-3680 (2003).
120. Yang Y, Lovett-Racke AE, Racke MK. Regulation of immune responses and autoimmune encephalomyelitis by PPARs. PPAR Res. 2010, 104705 (2010).
121. Klotz L, Burgdorf S, Dani I et al. The nuclear receptor PPARγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206(10), 2079-2089 (2009).
122. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ. Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130(4), 572-588 (2010).
123. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor γ (PPARγ) and immunoregulation: enhancement of regulatory T cells through PPARγ-dependent and-independent mechanisms. J. Immunol. 178(7), 4129-4135 (2007).
124. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor γ is required for regulatory CD4+ T cell-mediated protection against colitis. J. Immunol. 178(5), 2940-2949 (2007).
125. Spaner D, Lee E, Shi Y et al. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 27(5), 1090-1099 (2012).
126. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J. Immunol. 182(12), 7625-7633 (2009).
127. Repa JJ, Liang G, Ou J et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14(22), 2819-2830 (2000).
128. Cui G, Qin X, Wu L et al. Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J. Clin. Invest. 121(2), 658-670 (2011).
129. Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr. Opin. Cell Biol. 19(2), 215-222 (2007).
130. Geyeregger R, Shehata M, Zeyda M et al. Liver X receptors interfere with cytokineinduced proliferation and cell survival in normal and leukemic lymphocytes. J. Leukoc. Bio. 86(5), 1039-1048 (2009).
131. Michalek RD, Gerriets VA, Nichols AG et al. Estrogen-related receptor-α is a metabolic regulator of effector T-cell activation and differentiation. Proc. Natl Acad. Sci. USA 108(45), 18348-18353 (2011).
132. Nishikawa M, Uemura Y, Komada F, Ohno T, Katayama N, Shirakawa S. Clinical response to Busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect. Jpn. J. Clin. Oncol. 18(4), 327-333 (1988).
133. Cobbold SP, Adams E, Farquhar CA et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106(29), 12055-12060 (2009).
134. Sundrud MS, Koralov SB, Feuerer M et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324(5932), 1334-1338 (2009).
135. Kurebayashi Y, Nagai S, Ikejiri A et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep. 1(4), 360-373 (2012).
136. Nakamura H, Makino Y, Okamoto K et al. TCR engagement increases hypoxia-inducible factor-1α protein synthesis via rapamycinsensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 174(12), 7592-7599 (2005).
137. D'addio F, Riella LV, Mfarrej BG et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J. Immunol. 187(9), 4530-4541 (2011).
138. Palacios F, Abreu C, Prieto D et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia 29(1), 115-125 (2014).
139. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro. Int. J. Cancer 133(1), 247-252 (2013).
140. Mucida D, Park Y, Kim G et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317(5835), 256-260 (2007).
141. Joshi S, Pantalena L-C, Liu XK et al. 1, 25-Dihydroxyvitamin D3 ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 31(17), 3653-3669 (2011).
142. Aref S, Ibrahim L, Azmy E. Prognostic impact of serum 25-hydroxivitamin D [25 (OH) D] concentrations in patients with lymphoid malignancies. Hematology 18(1), 20-25 (2013).
143. Chen H, Qin J, Wei P et al. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukot. Essent. Fatty Acids 80(4), 195-200 (2009).
144. Runarsson G, Liu A, Mahshid Y et al. Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. Blood 105(3), 1274-1279 (2005).
145. Ryan EP, Pollock SJ, Kaur K et al. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin. Immunol. 120(1), 76-90 (2006).
146. Ayyoub M, Deknuydt F, Raimbaud I et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor RORγt. Proc. Natl Acad. Sci. USA 106(21), 8635-8640 (2009).
147. Ichiyama K, Yoshida H, Wakabayashi Y et al. Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J. Biol. Chem. 283(25), 17003-17008 (2008).
148. Koenen HJ, Smeets RL, Vink PM, Van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112(6), 2340-2352 (2008).
149. Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res. Int. 2014, 265840 (2014).
150. Tausch E, Mertens D, Stilgenbauer S. Advances in treating chronic lymphocytic leukemia. F1000prime Rep. 6, 65 (2014).